Champions Oncology, Inc.
CSBR
$6.80
-$0.02-0.29%
NASDAQ
| 07/31/2025 | 04/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | 13.27% | -27.49% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 13.27% | -27.49% | |||
| Cost of Revenue | 9.96% | 9.88% | |||
| Gross Profit | 18.02% | -51.22% | |||
| SG&A Expenses | -8.48% | 15.01% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 3.08% | 12.19% | |||
| Operating Income | 70.42% | -138.10% | |||
| Income Before Tax | 76.99% | -143.47% | |||
| Income Tax Expenses | 110.85% | -660.87% | |||
| Earnings from Continuing Operations | 74.60% | -140.82% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 76.24% | -140.82% | |||
| EBIT | 70.42% | -138.10% | |||
| EBITDA | 88.71% | -126.96% | |||
| EPS Basic | 76.31% | -140.66% | |||
| Normalized Basic EPS | 77.08% | -136.83% | |||
| EPS Diluted | 76.31% | -143.03% | |||
| Normalized Diluted EPS | 77.08% | -138.61% | |||
| Average Basic Shares Outstanding | 0.25% | 0.39% | |||
| Average Diluted Shares Outstanding | 0.25% | -4.26% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||